TABLE 1.
Participants’ demographics.
| ADNI cohort | |||||
|
| |||||
| f/ma | Age (SD) (years)b | MMSE (SD)c | Education years (SD)d | CSF Aβ42§ (SD) (pg/ml)e | |
| CN | 78/74 | 73.6 (6.5) | 29.1 (1.1) | 16.6 (2.5) | 1395.2 (665.5) |
| EMCI | 132/109 | 71.4 (7.4) | 28.4 (1.6) | 15.9 (2.7) | 1206.9 (593.6) |
| LMCI | 69/60 | 72.2 (7.9) | 27.5 (1.9) | 16.6 (2.7) | 927.7 (499.5) |
| AD | 45/33 | 75.7 (8.6) | 23.0 (2.0) | 15.5 (2.8) | 696.7 (410.8) |
|
| |||||
| INSIGHT-preAD cohort | |||||
|
| |||||
| f/m | Age (SD) [years] | MMSE (SD) | max. primary/min. secondary education | CSF Aβ42§ (SD) [pg/ml] | |
|
| |||||
| SMC | 21/22 | 74.9 (3.3) | 28.8 (0.9) | 7/36 | 885.8 (362.7) |
aNot significantly different across groups, Chi2 = 0.94, 3 df, p = 0.82.
bSignificantly different across groups, ANOVA, F(3, 598) = 7.6, p < 0.0001.
cSignificantly different across groups, Kruskal-Wallis ANOVA, p < 0.0001.
dSignificantly different across groups, ANOVA, F(3, 598) = 5.23, p < 0.001.
eSignificantly different across groups, ANOVA, F(3, 598) = 32.4, p < 0.0001.
§CSF Aβ42 values from electrochemiluminescence immunoassays on an automated Elecsys cobas e 601 instrument.
$CSF Aβ42 values from a double antibody sandwich ELISA method (Innotest-Fujirebio®, Courtaboeuf, France).
CN, healthy controls; EMCI, early MCI cases; LMCI, late MCI cases; AD, AD dementia cases; SMC, subjective memory complaints.
For definition of diagnostic categories see “Study Participants” section of the main text.